Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1014

1.

Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.

Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J; HIV-NAT 017 Study Team.

Pediatr Infect Dis J. 2008 Jul;27(7):623-8. doi: 10.1097/INF.0b013e31816b4539.

PMID:
18520443
2.

Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J; HIV-NAT 017 Study Team.

Antivir Ther. 2009;14(2):241-8.

PMID:
19430099
3.

Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, Engchanil C, Ruxrungtham K, Burger D; HIV-NAT 017 Study Team.

Pediatr Infect Dis J. 2005 Oct;24(10):874-9.

PMID:
16220084
4.

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, Havens PL; PACTG 1038 Team.

Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83. doi: 10.1128/AAC.00224-08. Epub 2008 Jul 14.

5.

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.

Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K; Study Team.

HIV Med. 2007 Nov;8(8):529-35.

6.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D, Markowitz M, Follansbee S, Angel JB, McMahon D, Ho D, Devanarayan V, Rode R, Salgo M, Kempf DJ, Granneman R, Leonard JM, Sun E.

AIDS. 1999 Feb 4;13(2):213-24.

PMID:
10202827
7.

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.

Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B; Frankfurt HIV Cohort.

J Antimicrob Chemother. 2006 Nov;58(5):1024-30. Epub 2006 Sep 6.

8.

Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).

Walmsley SL, Katlama C, Lazzarin A, Arestéh K, Pierone G, Blick G, Johnson M, Meier U, MacGregor TR, Leith JG.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):429-40. doi: 10.1097/QAI.0b013e318160a529.

PMID:
18176328
9.

Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.

Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.

HIV Med. 2007 May;8(4):226-33.

10.

Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.

Hoffmann F, Notheis G, Wintergerst U, Eberle J, Gürtler L, Belohradsky BH.

Pediatr Infect Dis J. 2000 Jan;19(1):47-51.

PMID:
10643850
11.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children.

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083
12.

Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B; Staccato Thailand Study Group.

Antivir Ther. 2008;13(3):375-80.

PMID:
18572750
13.

Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

von Hentig N, Babacan E, Staszewski S, Stürmer M, Doerr HW, Lötsch J.

Antivir Ther. 2007;12(8):1237-46.

PMID:
18240863
14.

The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.

HIV Med. 2005 Mar;6(2):122-8.

15.

Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M.

Int J Immunopathol Pharmacol. 2005 Oct-Dec;18(4):729-35.

PMID:
16388722
16.

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.

Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann OT, von Overbeck J, Leduc D, Perrin L, Hirschel B.

AIDS. 1997 Oct;11(12):F95-9.

PMID:
9342060
17.

A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.

Mole L, Schmidgall D, Holodniy M.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):260-5.

PMID:
11464145
18.

Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.

Delaugerre C, Teglas JP, Treluyer JM, Vaz P, Jullien V, Veber F, Rouzioux C, Chaix ML, Blanche S.

J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1269-75.

PMID:
15385734
19.

Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A.

Ther Drug Monit. 2007 Apr;29(2):171-6.

PMID:
17417070
20.

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70.

PMID:
11981362
Items per page

Supplemental Content

Write to the Help Desk